Thus, in our study corticosteroid use did not reflect a baseline unfavorable condition beyond tumor type and there was no hint that successfully treating ICI immune-mediated toxicities with corticosteroids might ultimately impair anti-PD1/PD-L1 efficacy. The gene discussed is CD274; the disease is neoplasm.